4 Positives For Johnson & Johnson
Summary: Johnson & Johnson might be the worst performing big pharma stock YTD, but there’s
Summary: Johnson & Johnson might be the worst performing big pharma stock YTD, but there’s
Summary: Johnson & Johnson, the pharmaceutical giant with a 3.21% dividend yield, released financial results
Summary: Johnson & Johnson beats market estimates for revenue and EPS in Q2 FY24. A
Summary: Johnson & Johnson will announce its Q2 2024 results on Wednesday, July 17 before
Summary: Johnson & Johnson reported solid first quarter results and is also expecting mid-single digit
Summary: Johnson & Johnson shares have underperformed for years, with multiple contributing causes including upcoming
Summary: Johnson & Johnson stock prices have been consistently declining in the recent 1~2 years.
Summary: The Health Care sector has been stagnant while other areas of the stock market
Summary: Johnson & Johnson’s acquisition of Shockwave Medical is expected to benefit J&J’s investors due
Summary: Johnson & Johnson stock has continued to underperform the healthcare sector, worrying JNJ investors.